Tamoxifen News and Research RSS Feed - Tamoxifen News and Research

Tamoxifen is a drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen is a type of antiestrogen. Also called tamoxifen citrate.
Breakthrough reveals influence of schizophrenia’s 'Rosetta Stone' gene in brain development

Breakthrough reveals influence of schizophrenia’s 'Rosetta Stone' gene in brain development

Scientists have identified a critical function of what they believe to be schizophrenia's "Rosetta Stone" gene that could hold the key to decoding the function of all genes involved in the disease. [More]
Breast cancer survivors in Appalachia not taking life-saving follow-up treatment, new study finds

Breast cancer survivors in Appalachia not taking life-saving follow-up treatment, new study finds

Nearly a third of breast cancer survivors in Appalachia are not taking the critical, potentially life-saving follow-up treatment - despite having insurance that would pay for it, a troubling new study has found. [More]
Progesterone hormone can benefit breast cancer patients

Progesterone hormone can benefit breast cancer patients

AROUND half of all breast cancer patients could one day benefit from having the cheap and widely-available female hormone progesterone added to their treatment, according to Cancer Research UK funded research published in Nature today (Thursday). [More]
Concert Pharmaceuticals’ precision deuteration platform can enhance metabolic properties of drugs

Concert Pharmaceuticals’ precision deuteration platform can enhance metabolic properties of drugs

Substituting deuterium for certain hydrogen atoms in molecules has been shown to enhance the metabolic properties of a number of drugs and provides a promising approach to the discovery and development of innovative drug products. [More]
Hormones used in breast cancer treatment could affect disease progression, outcomes in some patients

Hormones used in breast cancer treatment could affect disease progression, outcomes in some patients

Recently, researchers have discovered that the hormone progesterone, an ingredient in contraceptives and menopausal hormone replacement therapies, might stimulate the growth of breast cancer cells that are resistant to anti-estrogen therapy and chemotherapy. [More]
University at Albany researcher receives $1.76 million NIH grant to explore role of vitamin D in breast cancer

University at Albany researcher receives $1.76 million NIH grant to explore role of vitamin D in breast cancer

Each year, about 230,000 new cases of breast cancer are diagnosed in women in the U.S. It remains the third leading cause of death, behind only heart disease and lung cancer. Of the new cases, about 20 percent of women will be diagnosed with "triple negative" breast cancer (TNBC), a deadly form of breast cancer that does not respond to standard treatments such as tamoxifen or aromatase inhibitors. [More]
New treatment option for postmenopausal women with non-invasive breast cancer

New treatment option for postmenopausal women with non-invasive breast cancer

Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), a common diagnosis of non-invasive breast cancer. In women over age 60, it works as well as tamoxifen. [More]
Botanical formula improves effect of tamoxifen drug in ER+ human breast cancer

Botanical formula improves effect of tamoxifen drug in ER+ human breast cancer

Researchers at the Cancer Research Laboratory, Methodist Research Institute, Indiana University Health found that a botanical formula for breast health inhibited the growth of estrogen receptor-positive (ER+) human breast cancer cells. More importantly, the researchers also found that the formula enhanced the anti-cancer benefits of the drug tamoxifen in the treatment of breast cancer. [More]
Study confirms that coffee inhibits growth of tumours, reduces risk of breast cancer recurrence

Study confirms that coffee inhibits growth of tumours, reduces risk of breast cancer recurrence

A number of research studies have shown that coffee helps to protect against breast cancer. A new study led by Lund University, has confirmed that coffee inhibits the growth of tumours and reduces the risk of recurrence in women who have been diagnosed with breast cancer and treated with the drug tamoxifen. [More]
New combination therapy could overcome treatment resistance, relapse in breast cancer

New combination therapy could overcome treatment resistance, relapse in breast cancer

Researchers from The University of Manchester working with drug development company Evgen Pharma, have developed a new combination of drugs which could overcome treatment resistance and relapse in breast cancer. [More]
Australian researchers find gene that drives aggressive form of triple-negative breast cancer

Australian researchers find gene that drives aggressive form of triple-negative breast cancer

Australian researchers have found that so-called 'triple-negative breast cancers' are two distinct diseases that likely originate from different cell types. This helps explain why survival prospects for women with the diagnosis tend to be either very good or very bad. [More]
Researchers and medical bodies explore ways to secure funds for womb cancer research

Researchers and medical bodies explore ways to secure funds for womb cancer research

A national group of researchers, medical bodies and charities, led by The University of Manchester is looking for help in setting the top priorities for fighting womb cancer, with a survey launched today (23 March 2015). [More]
Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs). [More]
Breast cancer survivors at increased risk of developing thyroid cancer, finds new study

Breast cancer survivors at increased risk of developing thyroid cancer, finds new study

Breast cancer survivors are at increased risk of developing thyroid cancer, especially within five years of their breast cancer diagnosis, according to a new analysis of a large national database. The study results will be presented Thursday at the Endocrine Society's 97th annual meeting in San Diego. [More]
Only 65% of breast cancer patients who undergo mastectomy receive postmastectomy radiation therapy

Only 65% of breast cancer patients who undergo mastectomy receive postmastectomy radiation therapy

Breast cancer patients who undergo a mastectomy should receive subsequent radiation treatment if their cancer has spread to four or more nearby lymph nodes, however, according to a new study, only 65 percent of these women are getting the recommended postmastectomy radiation therapy (PMRT). [More]
New drug gets FDA approval for treatment of women with advanced breast cancer

New drug gets FDA approval for treatment of women with advanced breast cancer

The U.S. Food and Drug Administration today approved a potentially groundbreaking new drug to treat women with advanced breast cancer, signaling a new treatment strategy to arrest tumor growth and extend the time before the cancer worsens. [More]
Breast cancer risk for women with atypical hyperplasia greater than previously thought, study finds

Breast cancer risk for women with atypical hyperplasia greater than previously thought, study finds

Women with atypical hyperplasia of the breast have a higher risk of developing breast cancer than previously thought, a Mayo Clinic study has found. Results of the study appear in a special report on breast cancer in the New England Journal of Medicine. [More]
Study sheds light on clinical and biological characteristics of male breast cancer

Study sheds light on clinical and biological characteristics of male breast cancer

Results of the EORTC10085/TBCRC/BIG/NABCG International Male Breast Cancer Program conducted in both Europe and in the United States and presented at the 2014 San Antonio Breast Cancer Symposium found significant improvement in survival for men with breast cancer, but this improvement was not as good as that observed for women. [More]
Three studies reveal effects of blocking androgen receptors in breast cancer

Three studies reveal effects of blocking androgen receptors in breast cancer

Three studies presented by University of Colorado Cancer Center researchers at the San Antonio Breast Cancer Symposium 2014 demonstrate the effects of blocking androgen receptors in breast cancer. [More]
Preventive effect of tamoxifen drug for breast cancer remains virtually constant for 20 years

Preventive effect of tamoxifen drug for breast cancer remains virtually constant for 20 years

The preventive effect of breast cancer drug 'tamoxifen' remains virtually constant for at least 20 years - with rates reduced by around 30 per cent - new analysis published in The Lancet Oncology reveals. [More]
Advertisement
Advertisement